X4 Pharma’s Mavorixafor Wins Positive CHMP Opinion for WHIM Syndrome

X4 Pharmaceuticals receives positive CHMP opinion for mavorixafor, the potential first EU therapy for ultra-rare WHIM syndrome. EC decision expected Q2 2026.